<DOC>
	<DOC>NCT01096862</DOC>
	<brief_summary>The purpose of this study is to explore the efficacy and safety of multiple, escalating doses of ASP015K when compared to placebo in subjects with moderate to severe plaque psoriasis.</brief_summary>
	<brief_title>A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis</brief_title>
	<detailed_description>Following completion of at least 1 week of study drug for all subjects in group 1, the Sponsor will review the safety information of these subjects prior to enrolling off-treatment subjects into the next dose group. Dose escalation will continue in this manner (unless stopping criteria are met) until all groups have completed the study.</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Subject has moderate to severe plaque psoriasis for 6 months or longer with at least 10% Body Surface Area (BSA) affected Subject must be a candidate for phototherapy and/or systemic therapy Subject has nonplaque psoriasis or druginduced psoriasis Subject is on systemic psoriasis therapy within 56 days or 5 halflives, whichever is longer, prior to first dose of study drug Subject has a positive TB skin test within 3 months of screening or at screening Subject has an abnormal chest xray</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>ASP015K</keyword>
</DOC>